Delcath Systems (DCTHD) versus Wright Medical Group (WMGI) Financial Analysis
Delcath Systems (OTCMKTS: DCTHD) and Wright Medical Group (NASDAQ:WMGI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.
Earnings & Valuation
This table compares Delcath Systems and Wright Medical Group’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Delcath Systems||$1.99 million||0.08||-$17.97 million||($1,377.67)||0.00|
|Wright Medical Group||$690.36 million||3.42||-$432.37 million||($2.65)||-8.49|
Risk and Volatility
Delcath Systems has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, Wright Medical Group has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
This is a summary of recent recommendations for Delcath Systems and Wright Medical Group, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wright Medical Group||0||4||8||0||2.67|
Wright Medical Group has a consensus target price of $32.22, suggesting a potential upside of 43.27%. Given Wright Medical Group’s higher possible upside, analysts clearly believe Wright Medical Group is more favorable than Delcath Systems.
This table compares Delcath Systems and Wright Medical Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wright Medical Group||-38.40%||-6.27%||-1.71%|
Wright Medical Group beats Delcath Systems on 9 of the 10 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
About Wright Medical Group
Wright Medical Group, Inc. is a global specialty orthopaedic company. The Company through Wright Medical Technology, Inc. (WMT) and other subsidiaries provides extremity and biologic solutions that enable clinicians to alleviate pain and restore the patients’ lifestyles. The Company operates through three segments: U.S., International and BioMimetic. The Company’s business includes products that are used in foot and ankle repair, upper extremity products and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and patients. The Company’s products include extremity hardware, foot and ankle hardware, upper extremity hardware and biologics.
Receive News & Stock Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related stocks with our FREE daily email newsletter.